Effects of protocol HX-97 on mobilization, collection and hematopoietic reconstitution of peripheral blood stem cells transplantation
Liu, T.; Jia, Y.; Lu, Z.; Qin, L.; Xu, C.; Wu, J.; Deng, C.
Hua Xi Yi Ke da Xue Xue Bao 30(4): 428-430
1999
ISSN/ISBN: 0257-7712 PMID: 11387960 Document Number: 504150
In order to enhance the effects of peripheral blood stem cell mobilization, collection and hematopoietic reconstitution, we observed and evaluated the effects of Protocol HX-97 on 22 patients who received allogeneic or autologous peripheral blood stem cell transplants from April 1997 to June 1999. rhG-CSF was used for mobilization at a dose of 300 micrograms/day for 6 days; the sixth dose was given an hour and a half before leukapheresis. High dose chemotherapy and rhG-CSF were given for autologous peripheral blood stem cell mobilization; the chemotherapy should be intensive enough to reduce the patients' peripheral WBC to less than 1.0 x 10(9)/L, and the beginning of using rhG-CSF should be just at the time of WBC's rising from the nadir. rhGM-CSF and rhG-CSF were given sequentially for hematopoietic reconstitution after transplantation. The results showed that leukaphereses were successfully performed for peripheral blood stem cell collection. Sixteen cases needed apheresis only once, and 6 cases needed it twice. The harvests were 2.5-10.7 x 10(8)/kg MNC, 2.5-20.0 x 10(6)/kg CD34+ cells (including 1.8-7.5 x 10(6)/kg CD34+CD33-, 0.7-12.5 x 10(6)/kg CD34+CD33+), and 3.5-6.3 x 10(5)/kg CFU-GM. Hematopoietic function recovered to > 0.5 x 10(9)/L of neutrophil count in allo-PBSCT at 14-20 days and in auto-PBSCT at 12-20 days, and to > 20 x 10(9)/L of platelet count in allo-PBSCT and in auto-PBSCT at 16-34 days and 16-28 days, respectively. At day +30 post-transplantation, chromosome analysis and DNA finger print assessment of bone marrow cells indicated that the patients' hematopoietic function had been reconstituted. This study suggests that Protocol HX-97 is an effective approach to mobilization of peripheral blood stem cell transplantation, and it is relatively cost-effective.